A world free of chronic pain

We want to give a new lease of life to chronic pain patients all over the world. With the development of VER-01, we have reached our first significant milestone.
Home Hero

Our vision and mission

VERTANICAL is a globally leading biopharmaceutical company specializing in the development and distribution of innovative therapies for the treatment of chronic pain. Everything we do is guided by a single, clear vision: A world free of chronic pain!
After more than eight years of dedicated research and development, we have developed VER-01 – a unique cannabinoid-based medication for the treatment of chronic pain. This breakthrough marks a key milestone on our journey toward realizing that vision.
Our goal was to develop a pain medication that goes beyond the purely analgesic (pain-relieving) effect of conventional pain treatments by providing significant relief also from symptoms commonly associated with chronic pain, such as sleep disorders and depressive moods.
Building on our success in clinical development, we are pursuing the ambitious mission of establishing VER-01 as the leading therapy for chronic pain by 2030, setting new standards in pain management.

A world free of
chronic pain

Our vision
Union

Despite the treatments currently available, millions of patients continue to suffer from significant pain

Over a billion people worldwide suffer from chronic pain, often accompanied by sleep disorders and depression. Unlike acute pain, which serves an important protective function, chronic pain has no physiological purpose.
Neuroscientific research has shown that in chronic pain conditions, the brain becomes hypersensitive, transmitting pain signals even in the absence of actual physical stimuli.
Despite the range of treatments currently available – particularly opioids – many patients experience inadequate pain relief, with little to no improvement in related symptoms such as sleep disorders or depressive moods. Moreover, the majority of chronic pain patients endure significant side effects from their prescribed therapies.
As a result, chronic pain remains a persistent daily burden for over 400 million people globally, profoundly impacting their quality of life.

Our mission is to establish VER-01 as the leading therapy for the treatment of chronic pain by 2030

Our mission
Union

Pioneering innovation in the treatment of chronic pain

We believe that research and development are the driving forces behind groundbreaking medical innovation. In order to improve the lives of chronic pain patients worldwide, we invest tens of millions of Euros annually into R&D.
Our efforts are led by a dedicated team of highly experienced professionals who design and oversee our clinical trials, working in close collaboration with an international network of several hundred research and trial centers across Europe and the United States.
In addition, we operate one of the world’s most advanced facilities for the development and manufacturing of biopharmaceuticals – fully compliant with the highest GMP standards.
With an extensive development program assessing the efficacy and safety of VER-01 in more than 20 pre-clinical and clinical trials, VERTANICAL is among the leading innovators in chronic pain treatment. With the submission of our marketing application for the approval of VER-01 in Germany we have reached an important milestone for the treatment of chronic low back pain.

Our development pipeline

Chronic low back pain (CLBP)

Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Clinical trials
Trial code
EU
US
Clinical trials
show all
hide all
Evaluation of pharmacokinetics and safety in healthy volunteers
VER-PK-001
NCT04930809
Evaluation of pharmacokinetics and safety depending on the intake a high-fat meal in healthy volunteers
VER-PK-002
NCT04930796
Dose-response relationship
RESPONSE
NCT06475001
Efficacy, safety and maintenance of efficacy compared to placebo
VER-CLBP-001
NCT04940741
Tolerability, efficacy and safety compared to opioids
Efficacy and safety compared to placebo
Efficacy and safety compared to placebo
-
Planned

Osteoarthritis (OA)

Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Clinical trials
Trial code
EU/US
Clinical trials
show all
hide all
Efficacy, safety and maintenance of efficacy compared to placebo
-
Planned

Painful Diabetic Peripheral Neuropathy (PDPN)

Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Clinical trials
Trial code
EU/US
Clinical trials
show all
hide all
Efficacy, safety and maintenance of efficacy compared to placebo
-
Planned

Chronic low back pain (CLBP)

Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
EU
US
Clinical trials

show all

hide all

VER-PK-001
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Evaluation of pharmacokinetics and safety in healthy volunteers
Trial code
NCT04930809
VER-PK-002
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Evaluation of pharmacokinetics and safety depending on the intake a high-fat meal in healthy volunteers
Trial code
NCT04930796
RESPONSE
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Dose-response relationship
Trial code
NCT06475001
VER-CLBP-001
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Efficacy, safety and maintenance of efficacy compared to placebo
Trial code
NCT04940741
ELEVATE
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Tolerability, efficacy and safety compared to opioids
Trial code
NCT05610813
EXPAND
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Efficacy and safety compared to placebo
Trial code
NCT06956014
-
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Efficacy and safety compared to placebo
Trial code
Planned

Osteoarthritis (OA)

Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
EU/US
Clinical trials

show all

hide all

-
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Efficacy, safety and maintenance of efficacy compared to placebo
Trial code
Planned

Painful Diabetic Peripheral Neuropathy (PDPN)

Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
EU/US
Clinical trials

show all

hide all

-
Preclinical
Phase 1
Phase 2
Phase 3
Filed for registration
Efficacy, safety and maintenance of efficacy compared to placebo
Trial code
Planned
Mehr anzeigen

Our team

We are working together toward a world free of chronic pain, firmly believing that this vision can only be realized through perseverance and the courage to explore new frontiers. These guiding principles shape not only our approach to recruiting new talent but also define our management team’s approach.
Dr. Clemens Fischer

Dr. Clemens Fischer

Founder and shareholder
Learn more
Bastian Baasch

Bastian Baasch

Chief Executive Officer
Learn more
Sebastian Hach

Sebastian Hach

Chief Commercial Officer
Learn more

Our values

Our clearly defined values are the foundation of everything we do and the key to our success. We firmly believe that small, agile, and high-performing teams of exceptional individuals have the power to transform the treatment of chronic pain for the long term.
We believe in the power of small A‑teams
We are convinced that a small organisation of top-performers can achieve anything.
We embrace persistence
We believe persistence drives achievement. We refuse to accept "no" as an answer.
We continuously improve ourselves
We consistently question ourselves and challenge our views with credible people.
We strive for excellence
We hold ourselves to the highest standards in everything we do.
We uphold full transparency
We speak up and voice our opinions clearly.
We act with integrity
We stay away from anything illegal, dishonest, or immoral.

News

Vertanical In Faz
21.03.2025
Frankfurter Allgemeine Zeitung spotlights VERTANICAL’s promise in pain therapy
Handelsblatt Berichtet Vertanical Ver 01
17.03.2025
Handelsblatt features VERTANICAL as VER-01 moves toward regulatory approval
Vertanical In Der Times
17.03.2025
The Times: “Cannabis painkiller could replace opioids with no risk of addiction”
German Pain N Palliative Care Days Scaled
14.03.2025
VERTANICAL at the German Pain and Palliative Care Days in Frankfurt
Announces Results Phase3 Trial Ver 01
14.03.2025
VERTANICAL Presents Results of the Phase 3 Study on VER-01
04.12.2024
VERTANICAL Obtains GMP License for Danish Manufacturing Site
1 2 3
banner-teil-des-teams

Become part of our mission

Do you want to play an active role in bringing VER-01 to chronic pain patients and offer millions a new hope for a life free of chronic pain?
Visit our Careers page and apply for one of our many exciting opportunities!
Apply now